Provided by Tiger Trade Technology Pte. Ltd.

Immuneering Corp

5.23
+0.05000.97%
Volume:364.30K
Turnover:1.92M
Market Cap:337.70M
PE:-5.34
High:5.38
Open:5.20
Low:5.20
Close:5.18
52wk High:10.08
52wk Low:3.86
Shares:64.57M
Float Shares:49.21M
Volume Ratio:0.71
T/O Rate:0.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9796
EPS(LYR):-1.2729
ROE:-52.15%
ROA:-32.77%
PB:1.77
PE(LYR):-4.11

Loading ...

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

GlobeNewswire
·
Jun 01

Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and Cencora (COR)

TIPRANKS
·
May 22

Immuneering says atebimetinib-chemo trial shows 17.3-month median survival in pancreatic cancer

Reuters
·
May 22

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated With Atebimetinib Plus Chemotherapy

THOMSON REUTERS
·
May 22

Immuneering Corp - Only Anemia (16%) and Neutropenia (18%) Grade 3+ Adverse Events in ≥10% of Patients

THOMSON REUTERS
·
May 22

Immuneering Corp - Full Data From 55 Patients to Be Presented at Asco on June 1, 2026

THOMSON REUTERS
·
May 22

Immuneering Corp - Reports 17.3-Month Median Overall Survival as of April 24, 2026 Data Cutoff

THOMSON REUTERS
·
May 22

Immuneering Corp - Phase 3 Mapkeeper 301 Trial Recruiting; First Patient Dosing Expected Mid-2026

THOMSON REUTERS
·
May 22

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

GlobeNewswire
·
May 22

Immuneering Is Maintained at Buy by Chardan Capital

Dow Jones
·
May 20

Immuneering (IMRX) Gets a Buy from Chardan Capital

TIPRANKS
·
May 20

Mizuho Securities Sticks to Their Buy Rating for Immuneering (IMRX)

TIPRANKS
·
May 18

Analysts Are Bullish on Top Healthcare Stocks: Immuneering (IMRX), Galectin Therapeutics (GALT)

TIPRANKS
·
May 16

Immuneering posts smaller-than-expected Q1 net loss on lower R&D spend

Reuters
·
May 15

Immuneering Q1 FY26 net loss narrows to $13.5 million

Reuters
·
May 15

Immuneering Q1 EPS $(0.21) Beats $(0.26) Estimate

Benzinga Earnings
·
May 15

Immuneering Corp - Ends Q1 2026 With $198.6 Mln in Cash and Securities; Runway Into 2029

THOMSON REUTERS
·
May 15

Immuneering Corporation Q1 Net Income USD -13.5 Million VS. Ibes Estimate USD -17.3 Million

THOMSON REUTERS
·
May 15

Press Release: Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates

Dow Jones
·
May 15

Immuneering’s Phase 3 Pancreatic Cancer Trial Puts Atebimetinib in the Spotlight for IMRX Investors

TIPRANKS
·
May 08